Spinal cord motor neuron phenotypes and polygenic risk scores in sporadic amyotrophic lateral sclerosis: deciphering the disease pathology and therapeutic potential of ropinirole hydrochloride.

COI Statement

Competing interests: HO reports grants and personal fees as a chief scientific officer from K Pharma during the conduct of the study; personal fees from Sanbio, outside the submitted work; In addition, HO has a patent on a therapeutic agent for amyotrophic lateral sclerosis and composition for treatment licensed to K Pharma. QW is currently an employee of Calico Life Science. Involvement in the presented research was prior to the affiliation. The other authors have declared that no conflict of interest exists.